Online citations, reference lists, and bibliographies.
← Back to Search

Treatment Of Acid-Related Diseases In The Elderly With Emphasis On The Use Of Proton Pump Inhibitors

B. Thjódleifsson
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Proton pump inhibitors (PPIs) have revolutionised the treatment of acid-related disorders, and they have also made it possible to define the spectrum of acid inhibition required for optimal treatment in each disorder. Five PPIs are now available: the older drugs, omeprazole, lansoprazole and pantoprazole, and the two newest, rabeprazole and esomeprazole. These agents have predominantly been developed in the younger adult population, and data for the elderly population are limited. Subtle differences have emerged between the old and the new PPIs in their pharmacokinetic, pharmacodynamic and efficacy profiles. The degree of clinical relevance of these differences in the adult population is in question. However, according to this review, based on the available data for the elderly and by inference from the adult population, the differences are highly relevant in the elderly population.Studies of the pharmacokinetics of older PPIs demonstrated considerable variation in drug clearance that was reflected in a wide range of efficacy related to acid suppression with standard dosages. The newer PPIs offer several advantages over older agents, particularly in terms of rapid, profound and consistent acid inhibition. Consistent acid inhibition is particularly important in the elderly since clinical response is often difficult to judge in this patient group. An individual’s cytochrome P450 (CYP) 2C19 genotype predicts the degree of acid suppression and consequently the clinical efficacy of the PPIs. The older PPIs are predominantly metabolised by CYP2C19, with this being of more importance for omeprazole and lansoprazole than pantoprazole. The hepatic metabolism of rabeprazole is predominantly by nonenzymatic reactions and minimally by CYP-mediated reactions, which therefore confers an advantage over older PPIs in that genetic polymorphisms for CYP2C19 do not significantly influence rabeprazole clearance, clinical efficacy or potential for drug interactions. The metabolism of esomeprazole involves CYP2C19 but to a lesser extent than its predecessor omeprazole. Furthermore, esomeprazole has a more rapid onset of action and less variation in clearance rates than omeprazole. Drug clearance decreases with age independently of CYP2C19 status, exaggerating some of the differences between the PPIs and increasing the risk of drug interactions.
This paper references
10.1016/S0140-6736(75)91598-6
TREATMENT OF MALIGNANT MELANOMA
D. Harter (1975)
10.5555/URI:PII:0016508585906389
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.
R. Gugler (1985)
10.1016/0016-5085(85)90638-9
Omeprazole inhibits oxidative drug metabolism
R. Gugler (1985)
10.1111/J.1365-2125.1987.TB03209.X
Oral phenytoin pharmacokinetics during omeprazole therapy.
P. Prichard (1987)
10.1056/NEJM198901123200201
Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.
A. Walan (1989)
Functional dyspepsia : a classification with guidelines for diagnosis and management
N. Talley (1991)
10.1159/000200922
Safety experience from long-term treatment with omeprazole.
S. Joelson (1992)
10.1111/j.1532-5415.1992.tb03643.x
Prevalence and Characteristics of Symptomatic Gastroesophageal Reflux Disease in the Elderly
I.J. Räihä (1992)
10.1038/clpt.1992.172
Influence of lansoprazole treatment on diazepam plasma concentrations
Romain A Lefebvre (1992)
10.3109/00365529209028136
Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen.
E. Oddsson (1992)
10.1093/INFDIS/168.1.219
The cohort effect and Helicobacter pylori.
N. Banatvala (1993)
10.1111/J.1365-2125.1993.TB00398.X
Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects.
B. Flouvat (1993)
10.2165/00003495-199448010-00008
Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
M. Wilde (1994)
10.3109/00365529409105369
Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.
C. Howden (1994)
10.1093/AGEING/23.2.121
Comparison of omeprazole and histamine H2-receptor antagonists in the treatment of elderly and young patients with reflux oesophagitis.
O. James (1994)
10.3109/00365529409094875
Survey of prescriptions for peptic ulcer drugs (ACT class AOB2) in Iceland.
H. Thors (1994)
10.3109/00365529409096833
Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection.
L. Noach (1994)
10.1016/0016-5085(95)90571-5
Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion.
K. Gedda (1995)
Proton Pump Inhibitors Versus H2-Receptor Antagonists for the Treatment of Erosive Gastroesophageal Reflux Disease: A Cost-Comparative Study
M. Zagari (1995)
Lack of pantoprazole drug interactions in man: an updated review.
V. Steinijans (1996)
10.2165/00003495-199651030-00012
Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
A. Fitton (1996)
10.3109/00365529609036890
A quantitative analysis of symptoms of non-ulcer dyspepsia as related to age, pathology, and Helicobacter infection.
S. Lai (1996)
10.3109/00365529609036904
Seroprevalence of Helicobacter pylori in south Sweden and Iceland.
P. Bergenzaun (1996)
10.2165/00003088-199631010-00002
Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors
T. Andersson (1996)
Pharmacokinetics of pantoprazole in man.
R. Huber (1996)
10.1053/GAST.1996.V110.PM8612992
Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study.
M. Feldman (1996)
10.1097/00004836-199709000-00011
Omeprazole-induced interstitial nephritis.
D. Yip (1997)
[Lansoprazole-induced hepatitis].
C. VianadeMiguel (1997)
Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients.
J. Labenz (1997)
Laparoscopic Nissen fundoplication: where do we stand?
G. Perdikis (1997)
10.3109/00365529709007680
Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study.
G. Hasselgren (1997)
10.2165/00003495-199754030-00010
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
H. D. Langtry (1997)
10.1001/JAMA.1997.03550080069041
Gastric acidity in older adults.
A. Hurwitz (1997)
10.3109/00365529709007679
Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study.
O. B. Muckadell (1997)
10.1053/GAST.1997.V112.PM9178669
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.
N. Chiba (1997)
10.1136/gut.41.3.344
Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine
S. Somasundaram (1997)
10.1097/00042737-199710000-00006
The effect of Helicobacter pylori infection on NSAID‐related gastroduodenal damage in the elderly
A. Pilotto (1997)
10.1046/j.1365-2036.1997.146322000.x
Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output
A. W. Harris (1997)
10.1074/jbc.272.36.22438
Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents*
Marie Besancon (1997)
10.1016/S0016-5085(98)80729-4
Eleven years' experience of continuous maintenance treatment with omeprazole in gerd-patients
E. Klinkenberg-Knol (1998)
10.1111/j.1572-0241.1998.452_a.x
Has the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated?
L. Laine (1998)
10.1056/NEJM199803123381105
Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs
C. Hawkey (1998)
10.1136/bmj.317.7156.452
Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database
J. Bashford (1998)
10.1159/000028183
Differences in pH-Dependent Activation Rates of Substituted Benzimidazoles and Biological in vitro Correlates
W. Kromer (1998)
10.1155/1998/925346
The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts.
A. Thomson (1998)
10.1111/J.1572-0241.1998.00351.X
Laparoscopic Antireflux Surgery in the Elderly
T. Trus (1998)
10.1056/NEJM199803123381104
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.
N. Yeomans (1998)
10.1097/00063110-199812000-00016
Omeprazole and the development of acute hepatitis.
S. I. Koury (1998)
10.1046/j.1365-2036.1998.00426.x
Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily
Hatlebakk (1998)
10.1046/j.1365-2036.1998.00373.x
Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer—a European multicentre study
Dekkers (1998)
10.1046/j.1365-2036.1998.00418.x
A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjects
Williams (1998)
10.1046/j.1365-2036.1999.00035.x
Review article: rabeprazole’s tolerability profile in clinical trials
Thjodleifsson (1999)
10.1016/S0009-9236(99)70034-2
Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
T. Furuta (1999)
10.1097/00132586-199906000-00058
A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Anti-inflammatory Drugs
N. Yeomans (1999)
10.1136/gut.45.2.172
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification
L. Lundell (1999)
10.1046/j.1365-2036.1999.00616.x
Atrophic gastritis during long‐term omeprazole therapy affects serum vitamin B12 levels
Schenk (1999)
10.1136/gut.44.2008.S1
An evidence-based appraisal of reflux disease management — the Genval Workshop Report
J. Dent (1999)
Helicobacter pylori modulation of gastric acid.
J. Calam (1999)
10.1046/j.1365-2036.1999.00459.x
Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus—evaluation of 24‐h pH monitoring
Haruma (1999)
10.1007/s004649901116
Is laparoscopic antireflux surgery for gastroesophageal reflux disease in the elderly safe and effective?
L. Brunt (1999)
10.1016/S0009-9236(99)70075-5
CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans
T. Furuta (1999)
10.1046/j.1440-1746.1999.02012.x
Prevalence of non‐ulcer dyspepsia in the Japanese population
Kazuya Hirakawa (1999)
10.1001/ARCHINTE.159.7.649
Importance of pH control in the management of GERD.
R. Hunt (1999)
10.1046/j.1365-2036.1999.00449.x
Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study
Dekkers (1999)
10.1046/j.1365-2036.1999.00022.x
Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole
Ishizaki (1999)
10.1016/S0016-5085(00)82149-6
Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg
C. Wilder-Smith (2000)
10.1016/S0016-5085(00)84020-2
Effect of rabeprazole, lansoprazole and omeprazole on gastric ph during the early post-administration phase
Toshihito Saitoh (2000)
10.1046/J.1365-2125.2000.00262.X
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
R. Martin (2000)
10.1046/j.1365-2036.2000.00835.x
Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
M. Sagar (2000)
10.1046/j.1440-1746.2000.02131.x
Effect of age and Helicobacter pylori infection on gastric acid secretion
K. Haruma (2000)
10.1046/j.1365-2036.2000.00837.x
The control of gastric acid and Helicobacter pylori eradication
G. Sachs (2000)
10.1046/j.1365-2036.2000.00813.x
Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease
Lind (2000)
10.1046/j.1365-2036.2000.00703.x
Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline
Pan (2000)
10.1056/NEJM200008033430501
Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.
J. Lau (2000)
10.1046/j.1365-2036.2000.00829.x
Proton pump inhibitors: better acid suppression when taken before a meal than without a meal
J. Hatlebakk (2000)
An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori
S. V. V. Zanten (2000)
10.1016/S0016-5085(00)80818-5
Pharmacokinetics of esomeprazole are not affected by age: An assessment in the elderly
G. Hasselgren (2000)
10.1016/S0002-9270(00)01196-5
The future of acid suppression therapy trial with rabeprazole: preliminary analysis of acute symptom relief
L. Jokubaitis (2000)
10.1016/S0016-5085(00)84770-8
Esomeprazole 40mg and 20mg is efficacious in the long-term management of patients with endoscopy-negative gerd: A placebo-controlled trial of on-demand therapy for 6 months
N. Talley (2000)
10.1053/GAST.2000.16515
Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
M. Sagar (2000)
10.1046/j.1365-2036.2000.00804.x
Pantoprazole versus one‐week Helicobacter pylori eradication therapy for the prevention of acute NSAID‐related gastroduodenal damage in elderly subjects
A. Pilotto (2000)
Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding?
Geus Wp (2000)
10.1136/bmj.321.7262.659
Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia
P. Moayyedi (2000)
Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
A. Abelö (2000)
10.1046/j.1365-2036.2000.00840.x
CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole
K. Adachi (2000)
10.1046/j.1365-2036.2000.00878.x
Factors associated with consulting medical or non‐medical practitioners for dyspepsia: an Australian population‐based study
J. Westbrook (2000)
10.1155/2000/697943
Peptic disease in elderly patients.
N. Khaghan (2000)
10.1155/2000/702980
Appropriateness of omeprazole prescribing in Quebec's senior population.
J. Grégoire (2000)
10.1136/bmj.321.7270.1183
Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis
S. Derry (2000)
10.1067/mcp.2000.106826
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient
T. Furuta (2000)
10.2165/00002512-200118060-00003
Gastro-Oesophageal Reflux in the Elderly
A. Thomson (2001)
10.2165/00003088-200140060-00003
Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole
T. Andersson (2001)
10.1046/J.1365-2036.2001.00114.X
Role of proton pump inhibitors in non‐H. pylori‐related ulcers
J. Freston (2001)
10.1053/BEGA.2001.0193
Role of acid suppressants in intensive care medicine.
M. Tryba (2001)
10.1016/S0002-9270(01)02888-X
Rabeprazole 20 mg is more potent than esomeprazole 20 mg in control of gastric pH in healthy volunteers
K. Baisley (2001)
10.2165/00003088-200140020-00006
Pharmacokinetic Study of Esomeprazole in the Elderly
G. Hasselgren (2001)
10.1046/j.1365-2036.2001.01008.x
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole
A. Pilotto (2001)
10.1016/S0009-9236(01)28055-2
Effect of high‐dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19
T. Furuta (2001)
10.1046/j.1365-2036.2001.01050.x
Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors
S. Xue (2001)
10.1097/00004836-200104000-00005
Increased Numbers of Women, Older Individuals, and Blacks Receive Health Care for Dyspepsia in the United States
L. Rabeneck (2001)
10.1080/00498250110035615
Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole
S. Furuta (2001)
10.1067/mcp.2001.113959
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
T. Furuta (2001)
10.1053/BEGA.2001.0190
Problems related to acid rebound and tachyphylaxis.
D. Gillen (2001)
10.1046/j.1365-2036.2001.00972.x
The Loiano‐Monghidoro population‐based study of Helicobacter pylori infection: prevalence by 13C‐urea breath test and associated factors
F. Bazzoli (2001)
10.1046/j.1365-2036.2001.00943.x
Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6 months
N. Talley (2001)
10.1093/GERONA/56.8.M514
Survey of primary care physicians' approach to gastroesophageal reflux disease in elderly patients.
C. Wilcox (2001)
10.1136/gut.49.4.495
Reducing community dyspepsia drug costs: a controlled trial
R. Valori (2001)
10.2165/00002512-200118070-00002
Helicobacter Pylori-Associated Peptic Ulcer Disease in Older Patients
A. Pilotto (2001)
10.2165/00003088-200140070-00004
Drug Interaction Studies with Esomeprazole, the (S)-Isomer of Omeprazole
T. Andersson (2001)
10.1053/BEGA.2001.0186
Current indications for acid suppressants in dyspepsia.
P. Bytzer (2001)
10.1136/gut.48.6.743
The importance of interleukin 1β inHelicobacter pylori associated disease
E. El-Omar (2001)
10.1186/1471-230X-1-2
Drug interaction: Omeprazole and Phenprocoumon
C. Enderle (2001)
10.1111/j.1572-0241.2001.3600_b.x
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial
J. Richter (2001)
Gastroesophageal reflux disease: extraesophageal manifestations and therapy.
D. Kr (2001)
10.2165/00044011-200121010-00009
Esomeprazole 40mg Capsules are Bioequivalent when Administered Intact or as the Contents Mixed with Applesauce
T. Andersson (2001)
10.1067/mcp.2001.114231
Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19
K. Yu (2001)
10.1046/j.1365-2036.2002.01181.x
Onset of symptom relief with rabeprazole: a community‐based, open‐label assessment of patients with erosive oesophagitis
M. Robinson (2002)
10.1016/S0140-6736(02)07273-2
Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis
Jia-qing Huang (2002)
10.1023/A:1005600831851
Attributable Risk of H. pylori in Peptic Ulcer Disease
T. Sugiyama (2004)



This paper is referenced by
10.1097/MEG.0000000000002018
Proton pump inhibitor therapy is associated with reduced survival following first-time transarterial chemoembolization in patients with hepatocellular carcinoma.
L. Sturm (2020)
10.1097/MEG.0000000000001499
Deleterious effect of proton pump inhibitors on the disease course of cirrhosis
Tamás Janka (2019)
10.1136/bmjspcare-2019-001916
Subcutaneous pantoprazole in an elderly, palliative care patient.
Hugues Michelon (2019)
10.1111/apt.13827
The impact of proton pump inhibitor therapy on patients with liver disease
H. Cole (2016)
The role of bacterial infections in liver cirrhosis
K. Sargenti (2016)
10.1111/apt.13061
Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis
G. Dultz (2015)
10.1111/jgh.12426
Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis
Jee Hye Kwon (2014)
Einfluss genetischer Polymorphismen auf das Ansprechen der antithrombotischen Therapie und die klinische Prognose bei kardiovaskulären Risikofaktoren
Ä. Direktor (2013)
10.1007/978-90-313-9265-0_15
Gastro-intestinale aandoeningen
E. Mathus-Vliegen (2013)
10.1097/MJT.0b013e318217a5d1
Implications of Over-the-Counter Proton Pump Inhibitors for Patient Counseling by Pharmacists
W. Simonson (2013)
10.1007/BF03319099
A Review of Pharmacogenetics of Adverse Drug Reactions in Elderly People
M. Cardelli (2012)
10.1007/s11377-012-0662-1
Säuresuppression im Alter
H. Koop (2012)
10.1016/j.cgh.2011.11.019
Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression.
Gati A. Goel (2012)
10.2165/00003495-200565001-00013
Safety of Potent Gastric Acid Inhibition
C. Prados (2012)
10.1007/978-1-60327-362-6_22
Drug–Nutrient Interactions in the Elderly
B. Kinosian (2009)
10.2165/00003088-200948030-00006
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin’s Lymphoma or Multiple Myeloma
D. Quinn (2009)
10.1111/j.1365-2036.2009.03962.x
Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis – results from the EXPO study
J. Labenz (2009)
10.1007/s10354-009-0708-2
Medikamenteninteraktionen in der Geriatrie
A. Storka (2009)
10.3748/WJG.14.2980
Proton pump inhibitors in cirrhosis: tradition or evidence based practice?
F. Lodato (2008)
10.2165/00002512-200825030-00003
Clinical Efficacy of Esomeprazole in the Prevention and Healing of Gastrointestinal Toxicity Associated with NSAIDs in Elderly Patients
C. Blandizzi (2008)
Medikamenteninteraktionen in der Gastroenterologie
A. Storka (2008)
10.1007/s11010-007-9657-5
The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits
S. Bastaki (2007)
10.1016/J.JAMDA.2007.07.001
Use of proton pump inhibitors and other acid suppressive medications in newly admitted nursing facility patients.
C. Glew (2007)
10.2165/00002512-200724100-00003
Bleeding Peptic Ulcer in the Elderly
A. Zullo (2007)
TEACHERS' TOPICS The Chemically Elegant Proton Pump Inhibitors
V. Roche (2006)
10.5688/AJ7005101
The chemically elegant proton pump inhibitors.
V. Roche (2006)
10.1157/13095825
Seguridad de la utilizacin de los inhibidores de la bomba de protones
J. Esplugues (2006)
10.1111/j.1368-5031.2005.00639.x
Recent advances in the treatment of GERD in the elderly: focus on proton pump inhibitors
A. Pilotto (2005)
10.2165/00003495-200565001-00013
Safety of potent gastric acid inhibition.
C. M. Argila (2005)
10.1016/S0755-4982(04)98731-3
Les nouveaux inhibiteurs de la pompe à protons, un progrès dans la prise en charge des maladies acido-peptiques ?
J. Korwin (2004)
10.1108/NFS.2011.41.6.448.1
Handbook of drug-nutrient interactions.
J. Boullata (2004)
10.1111/j.1365-2036.2004.02086.x
A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube
J. Freston (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar